Interactive Brokers Group Reports Brokerage Metrics and Other Financial Information for May 2025, includes Reg.-NMS Execution Statistics
GREENWICH, Conn., June 02, 2025--(BUSINESS WIRE)--Interactive Brokers Group, Inc. (Nasdaq: IBKR) an automated global electronic broker, today reported its Electronic Brokerage monthly performance metrics for May.
Brokerage highlights for the month included:
3.384 million Daily Average Revenue Trades (DARTs)1, 43% higher than prior year and 11% lower than prior month.
Ending client equity of $628.2 billion, 29% higher than prior year and 7% higher than prior month.
Ending client margin loan balances of $61.2 billion, 15% higher than prior year and 5% higher than prior month.
Ending client credit balances of $134.7 billion, including $5.4 billion in insured bank deposit sweeps2, 26% higher than prior year and 1% higher than prior month.
3.79 million client accounts, 32% higher than prior year and 2% higher than prior month.
196 annualized average cleared DARTs1 per client account.
Average commission per cleared Commissionable Order3 of $2.61 including exchange, clearing and regulatory fees. Key products:
May 2025
Average
Average Commission per
Order Size
Cleared Commissionable Order
Stocks
808 shares
$1.94
Equity Options
6.3 contracts
$3.61
Futures
3.1 contracts
$3.87
Futures include options on futures. We estimate exchange, clearing and regulatory fees to be 58% of the futures commissions.
Other financial information for Interactive Brokers Group:
GLOBAL4: The value of the GLOBAL, reported in U.S. dollars, increased by 0.04% in May and increased by 1.758% for the year to date.
In the interest of transparency, we quantify our IBKR PRO clients' all-in cost of trade execution below.
For the full multimedia release with graph see link:
https://www.interactivebrokers.com/MonthlyMetrics
Average U.S. Reg-NMS stock trade was $20,437 in May (dividing 2c by 1a in table below).
In May, IBKR PRO clients' total cost of executing and clearing U.S. Reg.-NMS stocks through IB was about 2.1 basis points of trade money5, as, measured against a daily VWAP6 benchmark (3.8 basis points net cost for the rolling twelve months).
IBKR PRO Clients' Reg.-NMS Stock Trading Expense Detail
All amounts are in millions, except %
Previous
Jun '24
Jul '24
Aug '24
Sep '24
Oct '24
Nov '24
Dec '24
Jan '25
Feb '25
Mar '25
Apr '25
May '25
12 Months
#1a - Number of orders
Buys
8.07
10.09
9.84
8.38
10.93
11.40
13.32
12.74
12.40
12.19
13.79
12.15
135.30
Sells
5.83
7.55
7.53
6.54
8.33
8.62
9.66
8.97
9.08
8.71
10.16
9.49
100.47
Total
13.90
17.64
17.37
14.92
19.26
20.02
22.98
21.71
21.48
20.90
23.95
21.65
235.77
#1b - Number of shares purchased or sold
Shares bought
3,305
3,855
4,154
3,614
4,645
4,744
5,517
5,223
4,946
5,047
6,008
5,659
56,716
Shares sold
3,100
3,767
3,960
3,436
4,390
4,497
5,232
4,868
4,738
4,804
5,850
5,212
53,853
Total
6,405
7,622
8,114
7,050
9,035
9,241
10,749
10,090
9,683
9,851
11,858
10,871
110,569
#2 - Trade money including price, commissions and fees
2a Buy money
$151,903
$189,920
$182,908
$155,758
$190,627
$204,300
$214,806
$208,418
$200,026
$216,767
$254,062
$222,977
$2,392,472
2b Sell money
$147,514
$191,745
$186,274
$154,825
$188,444
$201,932
$215,520
$203,359
$204,689
$218,670
$259,783
$219,486
$2,392,241
2c Total
$299,417
$381,664
$369,182
$310,583
$379,071
$406,232
$430,326
$411,778
$404,715
$435,437
$513,845
$442,463
$4,784,713
#3 - Trade value at Daily VWAP
3a Buy value
$151,684
$189,851
$182,849
$155,692
$190,537
$204,249
$214,660
$208,258
$199,957
$216,676
$254,052
$223,005
$2,391,469
3b Sell value
$147,417
$191,812
$186,440
$154,890
$188,493
$201,995
$215,621
$203,305
$204,744
$218,725
$259,985
$219,608
$2,393,037
3c Total
$299,101
$381,663
$369,289
$310,582
$379,030
$406,243
$430,281
$411,563
$404,702
$435,401
$514,038
$442,613
$4,784,506
#4 - Total trade expense, including commissions and fees, relative to Daily VWAP
4a Buys (2a-3a)
$219.1
$68.8
$58.6
$66.6
$90.7
$51.4
$145.7
$160.6
$68.5
$90.6
$9.6
($28.0)
$1,002.2
4b Sells (3b-2b)
($97.1)
$67.5
$166.0
$65.7
$49.6
$62.3
$100.9
($54.3)
$55.2
$55.2
$202.8
$122.0
$795.8
4c Total trade expense
$122.0
$136.3
$224.6
$132.3
$140.3
$113.8
$246.6
$106.4
$123.7
$145.8
$212.4
$94.0
$1,798.0
Trade expense as percentage of trade money
4c/2c
0.041%
0.036%
0.061%
0.043%
0.037%
0.028%
0.057%
0.026%
0.031%
0.033%
0.041%
0.021%
0.038%
#5 - Trade expense categories
5a Total commissions & fees
$30.4
$37.1
$38.1
$33.2
$41.9
$43.5
$47.4
$46.2
$45.5
$45.7
$52.7
$44.5
$506.2
5b Execution cost (4c-5a)
$91.6
$99.2
$186.5
$99.1
$98.4
$70.3
$199.2
$60.2
$78.2
$100.0
$159.7
$49.5
$1,291.9
#6 - Trade expense categories as percentage of trade money
Total commissions & fees (5a/2c)
0.010%
0.010%
0.010%
0.011%
0.011%
0.011%
0.011%
0.011%
0.011%
0.010%
0.010%
0.010%
0.011%
Execution cost (5b/2c)
0.031%
0.026%
0.051%
0.032%
0.026%
0.017%
0.046%
0.015%
0.020%
0.023%
0.031%
0.011%
0.027%
Net Expense to IB Clients
0.041%
0.036%
0.061%
0.043%
0.037%
0.028%
0.057%
0.026%
0.031%
0.033%
0.041%
0.021%
0.038%
The above illustrates that the rolling twelve months' average all-in cost of an IBKR PRO client U.S. Reg.-NMS stock trade was 3.8 basis points.
____________________________
Note 1: Daily Average Revenue Trades (DARTs) – customer orders divided by the number of trading days in the period.
Note 2: FDIC insured client bank deposit sweep program balances with participating banks. These deposits are not reported in the Company's statement of financial condition.
Note 3: Commissionable Order – a customer order that generates commissions.
Note 4: In connection with our currency diversification strategy, we have determined to base our net worth in GLOBALs, a basket of 10 major currencies in which we hold our equity. The total effect of the currency diversification strategy is reported in Comprehensive Income and the components are reported in (1) Other Income and (2) Other Comprehensive Income ("OCI") on the balance sheet. The effect of the GLOBAL on our comprehensive income can be estimated by multiplying the total equity for the period by the change in the U.S. dollar value of the GLOBAL during the same period.
Note 5: Trade money is the total amount of money clients spent or received, including all commissions and fees.
Note 6: Consistent with the clients' trading activity, the computed VWAP benchmark includes extended trading hours.
____________________________
More information, including historical results for each of the above metrics, can be found on the investor relations page of the Company's corporate web site, www.interactivebrokers.com/ir.
About Interactive Brokers Group, Inc.:
Interactive Brokers Group affiliates provide automated trade execution and custody of securities, commodities, foreign exchange, and forecast contracts around the clock on over 160 markets in numerous countries and currencies, from a single unified platform to clients worldwide. We serve individual investors, hedge funds, proprietary trading groups, financial advisors and introducing brokers. Our four decades of focus on technology and automation has enabled us to equip our clients with a uniquely sophisticated platform to manage their investment portfolios. We strive to provide our clients with advantageous execution prices and trading, risk and portfolio management tools, research facilities and investment products, all at low or no cost, positioning them to achieve superior returns on investments. Interactive Brokers has consistently earned recognition as a top broker, garnering multiple awards and accolades from respected industry sources such as Barron's, Investopedia, Stockbrokers.com, and many others.
Cautionary Note Regarding Forward-Looking Statements:
The foregoing information contains certain forward-looking statements that reflect the company's current views with respect to certain current and future events and financial performance. These forward-looking statements are and will be, as the case may be, subject to many risks, uncertainties and factors relating to the company's operations and business environment which may cause the company's actual results to be materially different from any future results, expressed or implied, in these forward-looking statements. Any forward-looking statements in this release are based upon information available to the company on the date of this release. The company does not undertake to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any statements expressed or implied therein will not be realized. Additional information on risk factors that could potentially affect the company's financial results may be found in the company's filings with the Securities and Exchange Commission.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250602304700/en/
Contacts
Contacts for Interactive Brokers Group, Inc.: media@ibkr.com.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Meridianbet Seals Sponsorship Deal with Aquatic Sports Association of Malta (ASA)
Two-year agreement expands Meridianbet and Golden Matrix's (GMGI) sports sponsorship portfolio across regulated European markets Aquatic Sports Association of Malta VALLETTA, Malta, June 04, 2025 (GLOBE NEWSWIRE) -- Meridianbet, the sports betting and iGaming division of Golden Matrix Group Inc. (NASDAQ: GMGI), a leading developer and licensor of B2B and B2C gaming platforms, today announced the signing of a two-year exclusive sponsorship agreement with the Aquatic Sports Association of Malta (ASA), the official governing body for water polo, swimming, and artistic swimming in Malta. Under the terms of the agreement, Meridianbet becomes the exclusive betting partner of ASA, gaining integrated brand exposure across ASA events, digital platforms, and physical venues. The sponsorship includes the launch of the branded national cup competition - Meridianbet Super Cup, as well as LED road signage, scoreboard branding, and apparel sponsorships across Malta's aquatic sports federations. 'Water polo and aquatic sports are a vital part of Malta's sporting culture,' said Stefan Pavlovic, Malta territory director at Meridianbet. 'This partnership reflects our continued commitment to supporting national sports ecosystems, building long-term brand visibility in regulated markets, and delivering value to fans, players, local institutions and shareholders.' The ASA partnership builds on Meridianbet's growing sponsorship portfolio across 25+ international jurisdictions, where it supports sports ranging from football, basketball and MMA to eSports and grassroots competitions. This announcement also aligns with Meridianbet's broader ESG strategy. In 2024 alone, the company conducted 293 community engagement initiatives, reaching over 18,000 direct and indirect beneficiaries through education, healthcare, sports, and advocacy programs. Key Highlights of the Deal: Meridianbet named exclusive betting partner of Malta's ASA (governing body for water polo, swimming, artistic swimming) Launch of the Meridianbet Super Cup Brand exposure via LED ads, digital platforms, and team apparel To learn more about Meridianbet's community impact programs, visit About Meridianbet Founded in 2001, Meridianbet Group is a well-established online sports betting and gaming group, licensed and currently operating in 18 jurisdictions across Europe, Africa, and South America. The Meridianbet Group's successful business model utilizes proprietary technology and scalable systems, allowing it to operate in multiple countries and currencies with an omni-channel approach to markets, including retail, desktop online, and mobile. The Company is part of the Golden Matrix Group (Nasdaq: GMGI). For more information, visit IR Presentation - YouTube - Twitter - Email: ir@ A photo accompanying this announcement is available at
Yahoo
11 minutes ago
- Yahoo
Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial
Sionna Therapeutics, Inc. (NASDAQ:SION) released data from its Phase 1 trials of SION-719 and SION-451, the company's first-in-class nucleotide-binding domain 1 (NBD1) stabilizers, in healthy volunteers. One hundred subjects were dosed in the SION-719 trial, and 110 subjects were dosed in the SION-451 trial. Data Highlights Both NBD1 stabilizers were generally well tolerated and achieved pharmacokinetic (PK) concentration targets established using Sionna's preclinical cystic fibrosis (CF) human bronchial epithelial (CFHBE) data reinforce the potential of both NBD1 stabilizers to provide clinically meaningful benefit for CF patients, including the potential for wild-type CFTR function, either as an add-on to standard of care (SOC), or in a proprietary dual combination with complementary modulators. Both compounds were generally well tolerated in the Phase 1 trials. There were no serious adverse events, treatment-emergent adverse events (TEAEs) that led to discontinuation of the drug, or dose-limiting TEAEs observed. Most TEAEs were mild to moderate. One Grade 1 TEAE related to liver function tests (LFTs) was observed in a SION-451-treated subject who tested positive for influenza; no TEAEs related to LFTs were observed in the other cohorts of SION-451. There were no TEAEs related to LFTs in SION-719-treated subjects. The data from Part C of each trial support the use of a tablet formulation in future studies and indicate that both compounds can be dosed in a fed or fasted state. SION-719 and SION-451 achieved the desired target PK concentrations at multiple doses twice daily. Both stabilizers met exposure thresholds that can provide clinically meaningful benefit if administered as an add-on to SOC or in a proprietary dual combination with complementary modulators. Next Steps For SION-719: Sionna is progressing SION-719 into a Phase 2a POC trial evaluating the compound as an add-on to SOC in CF patients. Sionna is on track to initiate this trial in the second half of 2025, with topline data anticipated in mid-2026. The U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for SION-719. The first subject has been dosed in a midazolam drug-drug interaction (DDI) study to confirm that SION-719 can be dosed in combination with the SOC according to its label. The study will be completed before the Phase 2a trial is initiated. Next Steps For SION-451: Sionna plans to initiate a Phase 1 healthy volunteer dual combination trial evaluating SION-451 combined with SION-2222 (galicaftor) and SION-109. The trial will assess the safety, tolerability, and PK of varying doses of the dual combinations. It will inform the selection of a dual combination for a Phase 2b trial in CF patients. Sionna is on track to initiate the healthy volunteer trial in the second half of 2025, with topline data expected in mid-2026. In February, Sionna Therapeutics closed its upsized initial public offering of 12.18 million shares at $18.00 per share, with approximately $219.2 million in gross proceeds. Price Action: SION stock is trading higher by 6.80% to $15.47 at last check Wednesday. Read Next:Photo by Gorodenkoff via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Yahoo
28 minutes ago
- Yahoo
Industrias Unidas, S.A. de C.V. Consolidated Results of Operations for Q1 2025
MEXICO CITY, June 04, 2025--(BUSINESS WIRE)--Industrias Unidas, S.A. de C.V. ("IUSA" or the "Company") has announced its unaudited results for the three months ended March 31 of 2025. Figures are unaudited and have been prepared in accordance with Mexican Financial Reporting Standards ("MFRS"), which are different in certain respects from Generally Accepted Accounting Principles in the United States ("U.S. GAAP"). The results from any interim period are not necessarily indicative of the results that may be expected for a full fiscal year. Unless stated otherwise, reference herein to "Pesos", "pesos", or "Ps." are to pesos, the legal currency of Mexico and references to "U.S. dollars", "dollars", "U.S. $" or "$" are to United States dollars, the legal currency of the United States of America. Except as otherwise indicated, all peso amounts are presented herein in pesos with purchasing power as of March 31, 2025, and in pesos with their historical value for other dates cited. The dollar translations provided in this document are calculated solely for the convenience of the reader using an exchange rate of Ps. 20.46 per U.S. dollar, the exchange rate published by Banco de Mexico, the country's central bank, on March 31, 2025. Three months ended March 31, 2025, compared to three months ended March 31, 2024. The following table summarizes our results of operations for the three months ending March 31, 2025, and 2024: (Figures in Millions of Pesos) For the year ended March31, 2024 2025 Revenues 6,236.3 8,876.0 Cost of Sales 4,803.3 6,922.3 Gross Profit 1,433.0 1,953.7 Selling and Administrative Expenses 630.8 805.4 Operating Income (Loss) 802.2 1,148.3 Other Expenses - Net 51.2 21.8 Comprehensive Financing Result 63.8 34.9 Taxes and Statutory Employee Profit Sharing 180.9 290.4 Equity in Income (Loss) of Associated Companies (16.0) (2.8) Consolidated Net Income (Loss) 720.3 911.8 D&A 71.5 82.2 EBITDA 1/ 873.7 1,230.5 1/ EBITDA for any period is defined as consolidated net income (loss) excluding i) depreciation and amortization, ii) total net comprehensive financing result (which is comprised of net interest expense, exchange gain or loss, monetary position gain or loss and other Financing costs), iii) other expenses net, iv) income tax and statutory employee profit sharing and v) equity in income (loss) of associated companies. EBITDA should not be considered as an alternate measure of net income or operating income, as determined on a consolidated basis using amounts derived from statements of operations prepared in accordance with MFRS, or as an indicator of operating performance or to cash flows from operating activity as a measure of liquidity. EBITDA is not a recognized term under MFRS or U.S. GAAP and does not purport to be an alternative to net income as a measure of operating performance or to cash flows from operating activity as a measure of liquidity. Our consolidated net income for the three months ended March 31, 2025, was Ps.911.8 million (U.S.$44.6 million), compared to a net income of Ps.720.3 million in the same period of 2024. This represented a 26.6% increase, quarter over quarter (Q/Q). This change is primarily due to an increase in sales and hence Gross Profit. Revenues Our net revenues for the three months of 2025 increased 42.3% to Ps.8,876.0 million (U.S.$433.82 million) from Ps.6,236.3 million in the same period of 2024. This increase was driven in part by higher copper prices, combined with an increase in volume of sales. Our costs and revenues follow copper prices very closely since the market practice is to pass on to the buyer changes in raw material prices. Our sales are primarily for customers engaged in commercial, industrial and residential construction, and their related maintenance and renovation activities. We also sell to customers engaged in electrical power generation, transmission and distribution and to the sectors of gas, water and air conduction in Heating, Ventilation, Air conditioning and Refrigeration (HVACR). Our revenues consist mainly of sales of copper-based products (tubing, wire, cable and alloys) and electrical products. By country of production, approximately 61.3% of our revenues in the three months ended March 31, 2025, came from products manufactured in Mexico and the remaining 38.7% from products manufactured in the U.S. In terms of sales by region during the three months ended March 31, 2025, we derived approximately 44.0% of our revenues from sales to customers in the United States, 51.7% from customers in Mexico and 4.3% from the rest of the world ("ROW"). Cost of sales Our cost of sales in the three months ended March 31, 2025, increased by 44.1% to Ps.6,922.3 million (U.S.$338.3 million) from Ps.4,803.3 million in the same period of 2024. As a percentage of revenues, the cost of sales was 78.0% and 77.0% respectively. We reduce our cost base through several initiatives, including plant scheduling, raw material handling, and overall manufacturing overhead costs. According to our accounting policies, we make an inventory valuation at an average purchase price. In the case of copper cathodes, an aftermath adjustment is required due to the quotation period agreed with the suppliers (M+1). This initiative allows us to hedge purchases for 30 days at no additional cost. The adjustment is recorded to the cost of sales in the month in which it occurs. Gross Profit Our gross profit in the three months ended March 31, 2025, increased 36.3% to Ps.1,953.7 million (U.S.$95.5 million) from Ps.1,433.0 million in the same period of 2024. As a percentage of sales, gross profit in 2025 was 22.0% vs 23.0% in 2024. Selling and Administrative Expenses Our sales and administrative expenses in the three months ended March 31, 2025, increased 27.7% to Ps.805.4 million from Ps.630.8 in the same period of 2024. Operating Income Our operating income in the three months ended March 31, 2025, increased 43.1% to Ps. 1,148.3 million (U.S.$56.12 million) from an operating income of Ps. 802.2 in the same period of 2024. EBITDA In the three months ended March 31, 2025, our EBITDA increased 40.8% to Ps.1,230.5 million (or U.S.$60.1million), from Ps.873.7 million in the same period of 2024. The corresponding depreciation and amortization figures are Ps.422.3 million for January to March 2025 and Ps.337.7 million for the same period of 2024. Comprehensive Financing Result The following table shows our comprehensive financing results for the three months ending March 31, 2025, and 2024: (Figures in Millions of Pesos) For the year ended March 31, 2024 2025 Interest Expense (69.4) (78.5) Interest Income 51.3 30.6 Exchange Gain (Loss) - Net 88.7 88.9 Other Financing Costs (6.8) (6.1) Comprehensive Financing Result 63.8 34.9 Our comprehensive financing result in the three months ending March 31, 2025, was an expense of Ps.34.9 million, compared to an expense of Ps.63.8 million in the same period of 2024. Taxes and Statutory Employee Profit Sharing The provision for current and deferred income taxes and statutory employee profit sharing in the three months ended March 31, 2025, was an expense of Ps.290.4 million compared to an expense of Ps.180.9 million in the same period of 2024. Consolidated Net Income Our consolidated net income for the three months ended March 31, 2025, was Ps.911.8 million (U.S.$44.5 million), compared to a net income of Ps.720.3 million in the same period of 2024. Liquidity and Capital Resources Liquidity As of March 31, 2025, we had cash and cash equivalents for Ps.6,436.8 million (U.S.$314.6 million). Our policy is to invest available cash in short-term instruments issued by Mexican and U.S. banks as well as in securities issued by the governments of Mexico and the U.S. Our cash flow from operations and operating margins are significantly influenced by world market prices for raw copper, as quoted by COMEX and the London Metal Exchange ("LME"). Copper prices are subject to significant market fluctuations; average copper prices increased 18.4% in the three months ending March 31, 2025, to $4.57 US dollars per pound from $3.86 US dollar per pound in the same period of 2024. We obtain short-term financing from various sources, including Mexican and international banks. Short-term financing consists in part of lines of credit denominated in pesos and dollars. As of March 31, 2025, our outstanding short-term debt, including the current portion of long-term debt totaled Ps.422.2 million (U.S.$20.6 million), all of which was dollar denominated. On the same date, our outstanding consolidated long-term debt, excluding current portion thereof, totaled Ps.4,129.0 million (U.S.$201.8 million), all of which was dollar denominated. Accounts receivable from third parties as of March 31, 2025, were Ps.6,205.1 million (U.S.$303.3 million). Days outstanding in the domestic market were 31 days as of March 31, 2025. Debt Obligations The following table summarizes our debt as of March 31, 2025: Consolidated debt March 31, 2025 (In Millions of Pesos) U.S. subsidiaries debt 35.9 Mexican debt 4,515.4 Total 4,551.3 This total includes the restructured debt of the Company. Capital Expenditures For the three months ended March 31, 2025, we invested Ps.79.1 million (U.S. $3.9 million) in capital expenditure projects, mainly related to expansion of production and maintenance. In the three months ending March 31, 2025, our capital expenditures were allocated by segments as follows: 1.0% to copper tubing, 35.0% to wire and cable, 45.0% to valves and controls, 8.0% to electrical products and the remaining and 11.0% to other divisions. By geographic region 69.0% of total capital expenditures were invested in our Mexican facilities and the remaining 31.0% in the U.S. You should read this document in conjunction with the unaudited consolidated financial statements as of March 31, 2025, including the notes to those statements. View source version on Contacts Francisco Rodriguez, frodriguez@ tel. 5255 5216 4028